In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedPointe Inc.

Division of Mylan NV
www.medpointepharma.com

Latest From MedPointe Inc.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007

We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
BioPharmaceutical

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
BioPharmaceutical

Europe's New Spec Pharma Models

Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Europe North America

MedPointe's Private Dilemma

MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.
BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Carter-Wallace Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • Paul R Edick, Pres. & CEO
    Corey N Fishman, EVP, CFO
    Sue Foelix, VP, Mktg.
    Richard N Spivey, PhD, SVP, R&D
  • Contact Info
  • MedPointe Inc.
    Phone: (732) 564-2200
    265 Davidson Ave.
    Ste. 300
    Somerset, NJ 08873-4120
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register